Try our Advanced Search for more refined results
H. Lundbeck A S
-
Response | Filed: March 28, 2024 | Entered: March 28, 2024 H. Lundbeck A/S et al v. Lupin Limited, et al
Patent - Abbreviated New Drug Application(ANDA) | Delaware
Brief - Reply
REPLY BRIEF re 1111 MOTION for Attorney Fees for The Alembic Defendants pursuant to 35 U.S.C. § 285 filed by Alembic Global Holding S/A, Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited. (Pedi, Nicole)
-
Response | Filed: March 28, 2024 | Entered: March 28, 2024 H. Lundbeck A/S et al v. Lupin Limited, et al
Patent - Abbreviated New Drug Application(ANDA) | Delaware
Brief - Reply
[SEALED] REPLY BRIEF re 1105 Joint MOTION for Attorney Fees Defendants Macleod's and Sandoz's Motion for Attorney Fees Under 35 U.S.C. § 285 filed by Sandoz Inc.. (Attachments: # 1 Certificate of Service)(Gattuso, Dominick)
-
Misc | Filed: March 28, 2024 | Entered: March 28, 2024 H. Lundbeck A/S et al v. Lupin Limited, et al
Patent - Abbreviated New Drug Application(ANDA) | Delaware
Declaration
DECLARATION re 1129 Reply Brief, Declaration of Jason W. Schigelone in Support of Defendants Macleods's and Sandoz's Motion for Attorney Fees by Sandoz Inc.. (Attachments: # 1 Exhibit T-W)(Gattuso, Dominick)
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
- Archive of over 450,000 articles
- Database of over 2.1 million cases
- 62,000+ organization-specific pages.
- Daily and real-time news and case alerts on organizations, industries, and customized search queries.
- Significant legal events involving law firms, companies, industries, and government agencies.
- Learn more
TRY LAW360 FREE FOR SEVEN DAYS
Already a subscriber? Click here to login